TORRANCE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease? treatment, announced today the execution of a purchase agreement for up to $25 million of common stock with Lincoln Park Capital Fund, LLC (?LPC?), a long-only Chicago-based institutional investor.
Copyright © 2021 Biotech Networks, LLC
